SLNO Stock Soars Over 39% — What’s Fueling The Rally?

• The deal values Soleno at $53 per share, representing a 34% premium over the stock’s closing price on Friday, and is expected to close within three months.
• The deal adds Soleno’s genetic therapy to Neurocrine’s portfolio, the only approved therapy for hyperphagia in Prader-Willi Syndrome (PWS) with strong early adoption.
• PWS is a rare genetic disorder affecting roughly 10,000 people in the U.S.

Neurocrine Biosciences Inc. (NBIX) has agreed to acquire Soleno Therapeutics Inc. (SLNO) in a cash deal valued at approximately $2.9 billion to expand its footprint in rare diseases and endocrinology.

The agreement values Soleno shares at $53 each, representing a notable 34% premium over the stock’s closing price on Friday. The transaction, approved by both companies’ boards, is expected to close within about three months. 

Focus On Soleno Therapeutics’ Genetic Disorder Therapy 

The acquisition centers on adding Soleno’s therapy VYKAT XR (diazoxide choline), which targets hyperphagia associated with Prader-Willi syndrome (PWS). The condition, a rare genetic disorder affecting roughly 10,000 people in the U.S., leads to persistent hunger and severe health complications.

"Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader-Willi syndrome community, given their experience in endocrinology and rare disease and their proven ability to execute successful commercial launches.”

-Anish Bhatnagar, Chairman and CEO, Soleno

Following the announcement, Soleno Therapeutics’ stock traded over 39% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours. 

Strengthening Product Portfolio

Following the deal, Neurocrine will operate three key first-in-class therapies: INGREZZA, used to treat movement disorders; CRENESSITY, approved for congenital adrenal hyperplasia; and VYKAT XR, which entered the market in 2025.

Since its U.S. launch, VYKAT XR has seen strong early uptake. As the only approved treatment addressing hyperphagia in PWS, the drug is a primary therapy option, supported by intellectual property protections extending into the 2040s.

SLNO stock has declined by over 14% year-to-date. 

Also See: SoFi Gets A Price Target Cut From Barclays Ahead Of Q1 Earnings As Macro Pressures Weigh On Fintech Valuations

For updates and corrections, email newsroom[at]stocktwits[dot]com.